Moleculin Biotech, Inc.

NasdaqCM:MBRX Stock Report

Market Cap: US$5.5m

Moleculin Biotech Management

Management criteria checks 2/4

Moleculin Biotech's CEO is Wally Klemp, appointed in Jul 2015, has a tenure of 9.42 years. total yearly compensation is $1.41M, comprised of 39.9% salary and 60.1% bonuses, including company stock and options. directly owns 2.43% of the company’s shares, worth $132.74K. The average tenure of the management team and the board of directors is 7.2 years and 2.8 years respectively.

Key information

Wally Klemp

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage39.9%
CEO tenure9.4yrs
CEO ownership2.4%
Management average tenure7.2yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01
Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11
Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Mar 28
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 11
We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Aug 18
We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Moleculin Biotech to join Russell 2000 Index

Jun 15

CEO Compensation Analysis

How has Wally Klemp's remuneration changed compared to Moleculin Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$30m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$27m

Dec 31 2023US$1mUS$565k

-US$30m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$2mUS$565k

-US$29m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$2mUS$538k

-US$16m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$2mUS$500k

-US$17m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$625k

-US$13m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$1mUS$403k

-US$12m

Sep 30 2018n/an/a

-US$12m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$1mUS$325k

-US$10m

Compensation vs Market: Wally's total compensation ($USD1.41M) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Wally's compensation has been consistent with company performance over the past year.

CEO

Wally Klemp (64 yo)

9.4yrs

Tenure

US$1,414,599

Compensation

Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He Co-Founded Moleculin Biotech, Inc. in July 2015 and has been its Chief...

Leadership Team

NamePositionTenureCompensationOwnership
Walter Klemp
Co-Founder9.4yrsUS$1.41m2.43%
$ 132.7k
Jonathan Foster
Executive VP & CFO8.3yrsUS$840.64k0.38%
$ 20.7k
Donald Picker
Chief Scientific Officer7.3yrsUS$599.11k0.27%
$ 14.6k
Waldemar Priebe
Co-Founderno datano datano data
John Waymack
Senior Chief Medical Officer3.2yrsno datano data
Sandra Silberman
Chief Medical Officer of New Products7.1yrsno datano data
Wolfram C. Dempke
European Chief Medical Officer2.6yrsno datano data

7.2yrs

Average Tenure

69yo

Average Age

Experienced Management: MBRX's management team is seasoned and experienced (7.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Walter Klemp
Co-Founder9.4yrsUS$1.41m2.43%
$ 132.7k
Waldemar Priebe
Co-Founderno datano datano data
Michael Cannon
Independent Director8.5yrsUS$68.52k0%
$ 0
Jorge Cortes
Member of Scientific Advisory Board (SAB)less than a yearno datano data
Daniel Von Hoff
Member of Scientific Advisory Boardless than a yearno datano data
Michael Andreeff
Member of Scientific Advisory Board (SAB)less than a yearno datano data
John Climaco
Lead Independent Director7.4yrsUS$81.05k0%
$ 0
Elizabeth Cermak
Independent Director4.2yrsUS$63.52k0%
$ 0
Martin Tallman
Member of Annamycin Scientific Advisory Boardless than a yearno datano data
Robert George
Independent Director8.5yrsUS$74.90k0.033%
$ 1.8k
Joy Yan
Independent Director2.8yrsUS$47.15k0%
$ 0
Giovanni Martinelli
Member of Scientific Advisory Board (SAB)less than a yearno datano data

2.8yrs

Average Tenure

66yo

Average Age

Experienced Board: MBRX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:12
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Moleculin Biotech, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Kevin DeGeeterOppenheimer & Co. Inc.
null nullRoth MKM